Tarceva News and Research

RSS
Tarceva is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Tarceva is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib, erlotinib hydrochloride, and OSI-774.
ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

UCLA's Jonsson Comprehensive Cancer Center named one of nation's top 12 cancer centers

UCLA's Jonsson Comprehensive Cancer Center named one of nation's top 12 cancer centers

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

Astellas announces FDA acceptance of Tarceva sNDA for EGFR activating mutation-positive NSCLC

Astellas announces FDA acceptance of Tarceva sNDA for EGFR activating mutation-positive NSCLC

LRRK2 inhibitors may provide neuroprotection for patients with Parkinson's

LRRK2 inhibitors may provide neuroprotection for patients with Parkinson's

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

Anti-cancer EGFR inhibitors effective in reversing memory loss in animal models of Alzheimer's

Anti-cancer EGFR inhibitors effective in reversing memory loss in animal models of Alzheimer's

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Blocking AXL protein may prevent resistance to lung cancer drug

Blocking AXL protein may prevent resistance to lung cancer drug

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma third quarter revenue increases to $19.1M

Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

New data demonstrates anti-cancer activities of Oncoprex

New data demonstrates anti-cancer activities of Oncoprex

Clovis commences CO-1686 Phase I/II study in NSCLC

Clovis commences CO-1686 Phase I/II study in NSCLC

Survey reveals high interest in Xalkori among medical oncologists

Survey reveals high interest in Xalkori among medical oncologists